150 related articles for article (PubMed ID: 8582016)
1. Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds.
Ishizumi K; Kojima A; Antoku F; Saji I; Yoshigi M
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2139-51. PubMed ID: 8582016
[TBL] [Abstract][Full Text] [Related]
2. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Norman MH; Rigdon GC; Navas F; Cooper BR
J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.
Hirose A; Kato T; Ohno Y; Shimizu H; Tanaka H; Nakamura M; Katsube J
Jpn J Pharmacol; 1990 Jul; 53(3):321-9. PubMed ID: 1975278
[TBL] [Abstract][Full Text] [Related]
4. Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices.
Ishida K; Ohno Y; Ishibashi T; Nakamura M
Gen Pharmacol; 1996 Oct; 27(7):1203-7. PubMed ID: 8981068
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.
Hrib NJ; Jurcak JG; Bregna DE; Burgher KL; Hartman HB; Kafka S; Kerman LL; Kongsamut S; Roehr JE; Szewczak MR; Woods-Kettelberger AT; Corbett R
J Med Chem; 1996 Sep; 39(20):4044-57. PubMed ID: 8831770
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test.
Ohno Y; Ishida K; Ikeda K; Ishibashi T; Okada K; Nakamura M
Pharmacol Biochem Behav; 1994 Sep; 49(1):19-23. PubMed ID: 7816873
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
Yevich JP; New JS; Smith DW; Lobeck WG; Catt JD; Minielli JL; Eison MS; Taylor DP; Riblet LA; Temple DL
J Med Chem; 1986 Mar; 29(3):359-69. PubMed ID: 2869146
[TBL] [Abstract][Full Text] [Related]
8. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum.
Ishibashi T; Ikeda K; Ishida K; Yasui J; Tojima R; Nakamura M; Ohno Y
Eur J Pharmacol; 1996 May; 303(3):247-51. PubMed ID: 8813576
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
Norman MH; Rigdon GC; Hall WR; Navas F
J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
[TBL] [Abstract][Full Text] [Related]
10. In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain.
Takahashi Y; Kusumi I; Ishikane T; Koyama T
J Neural Transm (Vienna); 1998; 105(2-3):181-91. PubMed ID: 9660096
[TBL] [Abstract][Full Text] [Related]
11. Analogues of the potential antipsychotic agent 1192U90: amide modifications.
Navas F; Tang FL; Schaller LT; Norman MH
Bioorg Med Chem; 1998 Jun; 6(6):811-23. PubMed ID: 9681147
[TBL] [Abstract][Full Text] [Related]
12. Effect of linking bridge modifications on the antipsychotic profile of some phthalimide and isoindolinone derivatives.
Norman MH; Minick DJ; Rigdon GC
J Med Chem; 1996 Jan; 39(1):149-57. PubMed ID: 8568802
[TBL] [Abstract][Full Text] [Related]
13. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
14. Effects of perospirone, a novel 5-HT2 and D2 receptor antagonist, on Fos protein expression in the rat forebrain.
Ishibashi T; Tagashira R; Nakamura M; Noguchi H; Ohno Y
Pharmacol Biochem Behav; 1999 Aug; 63(4):535-41. PubMed ID: 10462181
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of a series of substituted N-alkoxyimides and -amides as potential atypical antipsychotic agents.
Hrib NJ; Jurcak JG; Huger FP; Errico CL; Dunn RW
J Med Chem; 1991 Mar; 34(3):1068-72. PubMed ID: 1672156
[TBL] [Abstract][Full Text] [Related]
16. New hexahydrocarbazoles and spiro indoles, and their affinity for D2 dopamine and 5-HT2A serotonin receptors.
Fernández F; García-Mera X; Rodríguez G; Urrutia A
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1006-9. PubMed ID: 10434402
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of heterocyclic carboxamides as potential antipsychotic agents.
Norman MH; Navas F; Thompson JB; Rigdon GC
J Med Chem; 1996 Nov; 39(24):4692-703. PubMed ID: 8941382
[TBL] [Abstract][Full Text] [Related]
18. Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 2: asymmetric synthesis and biological evaluation.
Zhao H; He X; Thurkauf A; Hoffman D; Kieltyka A; Brodbeck R; Primus R; Wasley JW
Bioorg Med Chem Lett; 2002 Nov; 12(21):3111-5. PubMed ID: 12372513
[TBL] [Abstract][Full Text] [Related]
19. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.
Perregaard J; Arnt J; Bøgesø KP; Hyttel J; Sánchez C
J Med Chem; 1992 Mar; 35(6):1092-101. PubMed ID: 1348090
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
